ABOUT PROMEDIOR: Management Team

SUZANNE BRUHN, Ph.D., President & Chief Executive Officer

Dr. Bruhn joined Promedior in May 2012 from Shire plc, where she was the Senior Vice President of Strategic Planning and Program Management in the Human Genetic Therapies division and she was responsible for the development of multiple protein therapeutics with annual sales today of over $1 billion.  During her 13 year tenure at Shire and Transkaryotic Therapies (acquired by Shire in 2005), she was instrumental in advancing new compounds through clinical development and commercialization with significant roles driving product strategy, portfolio management, program management, and global regulatory affairs for the rare disease portfolio. Prior to that she was at Cytotherapeutics, Inc., with a key role developing the encapsulated cell technology platform for ophthalmic delivery.  Dr. Bruhn is a member of the Board of Directors of Raptor Pharmaceuticals, a public biotechnology company, and the Crittenton Women’s Union, a local non-profit organization. She was a Postdoctoral Fellow in the Department of Human Genetics at Harvard Medical School and earned a Ph.D. in Chemistry from MIT and a B.S. from Iowa State University.

MARK L. LUPHER, JR., PH.D., Chief Scientific Officer

Dr. Lupher has been conducting biomedical research for nearly twenty years and has wide-ranging experience in the discovery and development of both biologic and small molecule drug candidates for the treatment of inflammatory and fibrotic diseases. He has authored numerous research articles, seminal reviews and book chapters and is the inventor on several issued and pending patent applications related to novel drug discovery. Prior to joining Promedior in 2007, Dr. Lupher held various R&D positions of increasing responsibility at biopharmaceutical companies such as Immunex and ICOS. While at ICOS, he pioneered the discovery of novel anti-fibrotic therapeutics and the development of the fibrotic disease therapeutic area. Dr. Lupher holds a B.S. degree in Microbiology from the University of Washington, a Ph.D. in Immunology from the Division of Medical Sciences at Harvard University and was a Post-Doctoral fellow at the Brigham and Women's Hospital.

JEFF EDELSON, M.D. – Interim Head of Clinical Development

Dr. Edelson has over 20 years of experience in clinical pharmacology, experimental and translational medicine, and clinical drug development at Johnson & Johnson, Aventis, and SmithKline Beecham.  Dr. Edelson is an Adjunct Professor of Medicine at the University of Pennsylvania, and was previously Director of Research and Academic Affairs at St. Michael’s Hospital in Toronto.  Dr. Edelson holds a M.D. degree from the University of Toronto and a B.S. degree from McMaster University. He is board certified in internal medicine.

W. SCOTT WILLETT, PH.D., Vice President of Biopharmaceutical Development

Dr. Willett has fourteen years of experience in the biopharmaceutical industry in development of protein purification processes for recombinant therapeutics. Prior to joining Promedior in 2007, Dr. Willett served as Director of Process Development at Neose Technologies, leading development and technology transfer for Phase I clinical manufacture of GlycoPEGylation™ processes for improved protein therapeutics. Before joining Neose, Dr. Willett was a Process Development Scientist at Amgen, where he led teams in development of Phase I cGMP purification processes for several proteins, in addition to supporting Amgen’s commercial products. Dr. Willett holds a Ph.D. in Pharmaceutical Chemistry from the University of California at San Francisco, and was an NSF Post-doctoral Fellow at the University of Colorado at Boulder. He also earned a B.S. degree in Chemical Engineering from the University of Michigan at Ann Arbor.

[ back to top ]